Skip Nav Destination
Drug Discovery
Nanomedicines: Design, Delivery and Detection
Edited by
Martin Braddock
Martin Braddock
AstraZeneca, UK
Search for other works by this author on:
Hardback ISBN:
978-1-84973-947-4
PDF ISBN:
978-1-78262-253-6
EPUB ISBN:
978-1-78262-751-7
Special Collection:
2016 ebook collection
Series:
Drug Discovery
No. of Pages:
370
Publication date:
14 Apr 2016
About this book
Nanomedicines and nanopharmacology is a rapidly developing and evolving field with new techniques and applications under constant development. This book will provide an overview of the chemistry of nanocarrier design and the considerations that need to be made when developing a nanomedicine. Providing an understanding of the relationship of nanocarrier, drug and targetting moieties and physico-chemical properties, this title will provide an accurate and current representation of the field by addressing the promises, prospects and pitfalls of nanomedicine. Covering a wide range of areas in detail, this book will provide an excellent companion for medicinal chemists, pharmacologists and biochemists working in industry or academia.
Nanomedicines: Design, Delivery and Detection, The Royal Society of Chemistry, 2016.
Download citation file:
Digital access
$251.00
Print format
Nanomedicines
$251.00
Table of contents
-
Chapter 1: Design Considerations for Properties of Nanocarriers on Disposition and Efficiency of Drug and Gene Deliveryp1-22ByJose Manuel Ageitos;Jose Manuel AgeitosEnzyme Research Team, Biomass Engineering Program Cooperation Division, RIKEN Center for Sustainable Resource Science2-1 HirosawaWako-shiSaitama 351-0198Japankeiji.numata@riken.jpSearch for other works by this author on:Jo-Ann Chuah;Jo-Ann ChuahEnzyme Research Team, Biomass Engineering Program Cooperation Division, RIKEN Center for Sustainable Resource Science2-1 HirosawaWako-shiSaitama 351-0198Japankeiji.numata@riken.jpSearch for other works by this author on:Keiji NumataKeiji NumataEnzyme Research Team, Biomass Engineering Program Cooperation Division, RIKEN Center for Sustainable Resource Science2-1 HirosawaWako-shiSaitama 351-0198Japankeiji.numata@riken.jpSearch for other works by this author on:
-
Chapter 2: Targeting Cyclins and Cyclin-dependent Kinases Involved in Cell Cycle Regulation by RNAi as a Potential Cancer Therapyp23-45ByManoj B. Parmar;Manoj B. ParmarFaculty of Pharmacy and Pharmaceutical Sciences, University of AlbertaEdmonton, ABCanadaSearch for other works by this author on:Hasan UludağHasan UludağFaculty of Pharmacy and Pharmaceutical Sciences, University of AlbertaEdmonton, ABCanadaDepartment of Chemical & Materials Engineering, Faculty of Engineering, University of AlbertaEdmonton, ABCanadaDepartment of Biomedical Engineering, Faculty of Medicine, University of AlbertaEdmonton, ABCanadahasan.uludag@ualberta.caSearch for other works by this author on:
-
Chapter 3: Nanoparticle Carriers to Overcome Biological Barriers to siRNA Deliveryp46-105ByHamidreza Montazeri Aliabadi;Hamidreza Montazeri AliabadiDepartment of Chemical & Material Engineering, Electrical & Computer Engineering Research Facility (ECERF), Faculty of Engineering, University of AlbertaEdmonton, ABCanadamontazer@chapman.eduhasan.uludag@ualberta.caSearch for other works by this author on:Hasan UludağHasan UludağDepartment of Chemical & Material Engineering, Electrical & Computer Engineering Research Facility (ECERF), Faculty of Engineering, University of AlbertaEdmonton, ABCanadamontazer@chapman.eduhasan.uludag@ualberta.caSearch for other works by this author on:
-
Chapter 4: Magnetic Targeting as a Vehicle for the Delivery of Nanomedicinesp106-119ByMitsuo Ochi;Mitsuo OchiDepartment of Orthopaedic Surgery, Graduate School of Biomedical Science, Hiroshima University1-2-3, KasumiMinami-kuHiroshimaJapanochim@hiroshima-u.ac.jpSearch for other works by this author on:Goki KameiGoki KameiDepartment of Orthopaedic Surgery, Graduate School of Biomedical Science, Hiroshima University1-2-3, KasumiMinami-kuHiroshimaJapanochim@hiroshima-u.ac.jpSearch for other works by this author on:
-
Chapter 5: The Development of Theranostics – Imaging Considerations and Targeted Drug Deliveryp120-150ByWa'el Al Rawashdeh;Wa'el Al RawashdehDepartment of Experimental Molecular Imaging, Rheinisch-Westfälische Technische Hochschule AachenAachenGermanySearch for other works by this author on:Siem Wouters;Siem WoutersDepartment of Biomedical NMR, Eindhoven University of TechnologyEindhovenThe Netherlandsfkiessling@ukaachen.deSearch for other works by this author on:Fabian Kießig;lingFabian Kießig;lingDepartment of Experimental Molecular Imaging, Rheinisch-Westfälische Technische Hochschule AachenAachenGermanySearch for other works by this author on:
-
Chapter 6: The Role of Imaging in Nanomedicine Development and Clinical Translationp151-181ByJinzi Zheng;Jinzi ZhengTECHNA Institute for the Advancement of Technology for Health, University Health NetworkTorontoOntarioCanadajinzi.zheng@rmp.uhn.on.caInstitute of Biomaterials and Biomedical Engineering, University of TorontoTorontoOntarioCanadaSearch for other works by this author on:Raquel De Souza;Raquel De SouzaFaculty of Pharmaceutical Sciences, University of TorontoTorontoOntarioCanadaSearch for other works by this author on:Manuela Ventura;Manuela VenturaTECHNA Institute for the Advancement of Technology for Health, University Health NetworkTorontoOntarioCanadajinzi.zheng@rmp.uhn.on.caSearch for other works by this author on:Christine Allen;Christine AllenTECHNA Institute for the Advancement of Technology for Health, University Health NetworkTorontoOntarioCanadajinzi.zheng@rmp.uhn.on.caFaculty of Pharmaceutical Sciences, University of TorontoTorontoOntarioCanadaSearch for other works by this author on:David JaffrayDavid JaffrayTECHNA Institute for the Advancement of Technology for Health, University Health NetworkTorontoOntarioCanadajinzi.zheng@rmp.uhn.on.caInstitute of Biomaterials and Biomedical Engineering, University of TorontoTorontoOntarioCanadaDepartment of Radiation Oncology, University of TorontoTorontoOntarioCanadaSearch for other works by this author on:
-
Chapter 7: Anticancer Agent-Incorporating Polymeric Micelles: from Bench to Bedsidep182-198ByYasuhiro MatsumuraYasuhiro MatsumuraDevelopmental Therapeutics, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center6-5-1 KashiwanohaKashiwa City277-8577Japanyhmatsum@east.ncc.go.jpSearch for other works by this author on:
-
Chapter 8: Polymeric Nanoparticles and Cancer: Lessons Learnt from CRLX101p199-232ByIsmael Gritli;Ismael GritliCollege of Medical Science and Technology, Taipei Medical University250-Wu-xing St. Xinyi DistrictTaipei11031TaiwanSearch for other works by this author on:Edward Garmey;Edward GarmeyCerulean Pharma Inc.840 Memorial DriveCambridgeMA 02139USASearch for other works by this author on:Scott Eliasof;Scott EliasofCerulean Pharma Inc.840 Memorial DriveCambridgeMA 02139USASearch for other works by this author on:Andres Tellez;Andres TellezCerulean Pharma Inc.840 Memorial DriveCambridgeMA 02139USASearch for other works by this author on:Mark E. Davis;Mark E. DavisChemical Engineering, California Institute of TechnologyPasadenaCA 91125USASearch for other works by this author on:Yen YunYen YunSearch for other works by this author on:
-
Chapter 9: Nanodelivery Strategies in Breast Cancer Chemotherapyp233-252ByLarn HwangLarn HwangSearch for other works by this author on:
-
Chapter 10: Developing a Predictable Regulatory Path for Nanomedicines by Accurate and Objective Particle Measurementp253-280ByAmy J. PhillipsAmy J. PhillipsSearch for other works by this author on:
-
Chapter 11: Nanomedicine: Promises and Challengesp281-289ByR. L. JulianoR. L. JulianoDivision of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North CarolinaChapel HillNC27599USAarjay@med.unc.eduSearch for other works by this author on:
-
Chapter 12: The Challenge of Regulating Nanomedicine: Key Issuesp290-314ByRaj Bawa;Raj BawaDepartment of Biological Sciences, Rensselaer Polytechnic InstituteTroy, New YorkUSASearch for other works by this author on:Yechezkel Barenholz;Yechezkel BarenholzLaboratory of Membrane and Liposome Research, Department of Biochemistry and Molecular Biology, Institute for Medical Research Israel – Canada (IMRIC), The Hebrew University-Hadassah Medical SchoolJerusalemIsraelSearch for other works by this author on:Andrew OwenAndrew OwenDepartment of Molecular and Clinical Pharmacology, University of LiverpoolUKSearch for other works by this author on:
-
Chapter 13: Doxil® – the First FDA-approved Nano-drug: from Basics via CMC, Cell Culture and Animal Studies to Clinical Usep315-345ByYechezkel (Chezy) BarenholzYechezkel (Chezy) BarenholzLaboratory of Membrane and Liposome Research, epartment of Biochemistry and Molecular Biology, Insitute for Medical Research Israel – Canada (IMRIC), Hebrew University-Hadassah Medical SchoolJerusalemIsraelchezyb@gmail.comchezyb@ekmd.huji.ac.ilSearch for other works by this author on:
Spotlight
Advertisement
Advertisement
